Abstracts

AGE, GENDER, AND RACE ANALYSES OF D/C/F/TAF IN HIV-1 TREATMENT NAÏVE PATIENTS

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the only single-tablet regimen in development for HIV-1 infection that contains darunavir and F/TAF. AMBER evaluated the efficacy and safety of D/C/F/TAF 800/150/200/10 mg versus control (D/C+F/tenofovir disoproxil fumarate [TDF]) in antiretroviral treatment (ART)-naïve, HIV-1–infected adults. We present Week 48 results based on age, gender, and race. In AMBER, a phase…

MONITORING THE IMPACT OF ART MODIFICATION WITH LONGITUDINAL FDG-PET IN SIV-MODEL

The aim of this study was to assess immune activation in various organs by longitudinally measuring changes in glucose metabolism associated with initiation and interruption of combination antiretroviral therapy (cART) in SIV-infected macaques. We also assessed the associations of various markers of disease activity with tissue metabolic activity. Whole body 18F-Fluorodeoxyglucose (FDG) PET-imaging was obtained…

SPREAD OF HIV-DNA IN CD4+ T-CELL SUBSETS DEPENDS ON ART INITIATION TIMING

Life-long resting CD4+ T-cells are the major long-lasting reservoir in HIV-infected individuals. The aim of our study is to analyze the dynamics of archived HIV-DNA in CD4+ T-cells subsets in individuals starting successful dolutegravir-based regimen over 48 weeks. Participants from the prospective longitudinal DRONE study (NCT02557997) including: treatment-naïve individuals who initiated treatment with a dolutegravir-based…

ADJUNCTIVE SERTRALINE IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS

Identifying new antifungals effective for cryptococcal meningitis (CM) remains a priority given the high costs, toxicity, and limited availability of current first line therapy. Sertraline has previously demonstrated in vitro and in vivo activity against Cryptococcus. We evaluated the efficacy of adjunctive sertraline for cryptococcal meningitis in a double-blind, randomized, placebo-controlled clinical trial. We assessed…